Additional Study Information: The purpose of this study is to see if a medicine called ASP2215 is both safe and effective as atreatment for patients with Acute Myeloid Leukemia (AML). ASP2215 is an experimental drug that is being studied to treat AML. In this study, ASP2215 will be given in addition to a standard chemotherapy regimen that patients could be receiving even if they were not participating in this study. The standard chemotherapy regimen patients receive includes cytarabine and idarubicin, however, there are other possible chemotherapy regimens they could receive depending on what their doctors thinks is best for them.